Top

Global Type 1 Diabetes Market 2016-2020

Category : Healthcare  | Published Date : March-2016 | Pages : 80
enquire GET DISCOUNT
About Type 1 Diabetes Drugs

Diabetes, often referred to as diabetes mellitus, results in high blood glucose levels. Depending on the cause of development, it can be divided into three types:
• Type 1 diabetes (or insulin-dependent diabetes mellitus): The pancreas do not produce the required amount of insulin in the body, leading to high blood glucose levels.
• Type 2 diabetes (non-insulin-dependent diabetes mellitus): In this condition, though the body produces the required amount of insulin, the cells do not respond to it. This results in a high glucose level in the body.
• Gestational diabetes: This condition occurs in pregnant women without any history of diabetes.
Type 1 diabetes is an autoimmune disorder characterized by high blood glucose levels. In this condition, the immune system is activated against insulin-producing cells. This condition hampers the bodys ability to produce insulin and disrupts blood glucose homeostasis. Type 1 diabetes differs from a more prevalent form of diabetes mellitus, type 2 diabetes, wherein the insulin is produced inside the body. Type 1 diabetes accounts for only 5%-15% of the total diabetes cases. As the disease is more prevalent among children and adolescents aged 0-15 years, it was earlier known as juvenile diabetes. Type 1 diabetes management relies on providing symptomatic relief and improving the quality of life of people.

Technavios analysts forecast the global type 1 diabetes drugs market to grow at a CAGR of 8.05% during the period 2016-2020.

Covered in this report 
The report covers the present scenario and the growth prospects of the global type 1 diabetes drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded drugs and biosimilars used to treat and prevent type 1 diabetes.

The market is divided into the following segments based on geography: 
• Americas
• APAC
• EMEA

Technavio's report, Global Type 1 Diabetes Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. 

Key vendors 
• Eli Lilly and Company
• Novo Nordisk A/S
• Sanofi SA 

Other prominent vendors 
• Adocia
• Astellas Pharma
• AstraZeneca
• Baxalta
• BHV Pharma
• Biocon
• Biodel
• Boehringer Ingelheim
• CureDM
• Dance Biopharm
• Diamyd Therapeutics AB
• Diasome Pharmaceuticals
• DiaVac 
• Exsulin
• Gan & Lee Pharmaceuticals
• Generex Biotechnology
• GlaxoSmithKline
• ILTOO Pharma
• Intrexon
• Islet Sciences
• Kamada 
• Kotobuki Pharmaceutical
• Lexicon Pharmaceuticals
• Living Cell Technologie 
• MacroGenics
• MannKind Pharmaceuticals
• Merck
• Merrion Pharmaceutical 
• Oramed Pharmaceuticals 
• Osiris Therapeutics 
• Perle Biosciences
• Pfizer
• REGiMMUNE
• Strongbridge Biopharma
• Toleranzia
• Tolerio
• Xeris Pharmaceuticals
• XOMA

Market driver 
• Increase in prevalence of type 1 diabetes
• For a full, detailed list, view our report 

Market challenge 
• Poor storage conditions and distribution policies for insulin
• For a full, detailed list, view our report 

Market trend 
• Awareness programs and initiatives
• For a full, detailed list, view our report 

Key questions answered in this report 
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors? 

You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.
PART 01: Executive summary 
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
Key buying criteria
PART 05: Disease overview
Introduction
Risk factors
Diagnosis
Management
Epidemiology
Economic burden
PART 06: Insulin: An overview
Product portfolio
Global human insulin market
PART 07: Pipeline analysis
Faster-acting insulin aspart (NN1218)
Farxiga/Forxiga
SAR342434
NN9211
LY2605541
Sotagliflozin
MK-1293
PRL001
Otelixizumab
PART 08: Reimbursement scenario in US
PART 09: Market landscape
Global diabetes drugs market
Global type 1 diabetes drugs market
Five forces analysis
PART 10: Market segmentation by drug class
Insulin
Others
PART 11: Geographical segmentation
Type 1 diabetes drugs market in Americas
Type 1 diabetes drugs market in EMEA
Type 1 diabetes drugs market in APAC
PART 12: Market drivers
Increase in prevalence of type 1 diabetes
Advances in insulin delivery technology
Rise in price of insulin drugs
Stringent regulatory conditions for biosimilar drugs
Promising drug pipeline
PART 13: Impact of drivers
PART 14: Market challenges
Side effects of current therapies
Fierce market competition
Poor storage conditions and distribution policies for insulin
Gap in nation-level diabetes management plans
Rising concerns in scientific community
PART 15: Impact of drivers and challenges
PART 16: Market trends
Development of drugs with novel mechanisms
Awareness programs and initiatives
Focus on emerging markets
Increase in academia-industry collaboration
PART 17: Vendor landscape
Competitive scenario
Market analysis 2015
Novo Nordisk
Sanofi
Eli Lilly
Other prominent vendors
PART 18: Appendix
List of abbreviations
PART 19: Explore Technavio
List of Exhibits?
Exhibit 01: Product offerings
Exhibit 02: Key buying criteria for type 1 diabetes drugs
Exhibit 03: Diagnostic test for diabetes based on blood sugar levels
Exhibit 04: Diagnostic test for diabetes based on glycated hemoglobin levels
Exhibit 05: Global human insulin market 2015-2020 ($ billions)
Exhibit 06: Pipeline portfolio: Global type 1 diabetes drugs market
Exhibit 07: Global diabetes drugs market by type of disease prevalence 2015
Exhibit 08: Top-selling diabetes drugs based on sales 2014 ($ billions)
Exhibit 09: Market share of global diabetes drugs in global pharmaceutical drugs market 2015
Exhibit 10: Global diabetes drugs market 2015-2020 ($ billions)
Exhibit 11: Market share analysis of vendors in global diabetes drugs market 2015
Exhibit 12: Global type 1 diabetes drugs market 2015-2020 ($ billions)
Exhibit 13: Five forces analysis
Exhibit 14: Segmentation of type 1 diabetes drugs market by drug class
Exhibit 15: Estimated market share of global type 1 diabetes drugs market by drug class 2020
Exhibit 16: Segmentation of global type 1 diabetes drugs market based on geography 2015
Exhibit 17: Type 1 diabetes drugs market revenue by geography 2015-2020 ($ billions)
Exhibit 18: Global type 1 diabetes drugs market by geography 2015-2020
Exhibit 19: Type 1 diabetes drugs market in Americas 2015-2020 ($ billions)
Exhibit 20: Type 1 diabetes drugs market in EMEA 2015-2020 ($ billions)
Exhibit 21: Type 1 diabetes drugs market in APAC 2015-2020 ($ billions)
Exhibit 22: Global type 1 diabetes drugs market: YoY growth and revenue based on geography 2015-2020
Exhibit 23: Impact of drivers
Exhibit 24: Impact of drivers and challenges
Exhibit 25: Revenues from sales of major products in type 1 diabetes market 2012-2014 ($ billions)
Exhibit 26: Novo Nordisk: Business segmentation by revenue 2015
Exhibit 27: Novo Nordisk: R&D expenditure 2015
Exhibit 28: Novo Nordisk: YoY revenue and growth rate generated from net product sales of human insulins 2012-2015 ($ billions)
Exhibit 29: Novo Nordisk: YoY revenue and growth rate generated from net product sales of Levemir 2012-2015 ($ billions)
Exhibit 30: Novo Nordisk: YoY revenue and growth rate of NovoRapid/NovoLog 2012-2015 ($ billions)
Exhibit 31: Novo Nordisk: Geographical split of revenues of NovoRapid/NovoLog, 2015
Exhibit 32: Novo Nordisk: YoY revenue and growth rate of NovoMix/NovoLog Mix 2012-2015 ($ billions)
Exhibit 33: Novo Nordisk: Geographical split of revenues of NovoMix/NovoLog Mix, 2015
Exhibit 34: Novo Nordisk: YoY revenue and growth rate generated from net product sales of new-generation insulins 2013-2015 ($ millions)
Exhibit 35: Novo Nordisk: Key takeaways
Exhibit 36: Sanofi: Business segmentation by revenue 2015
Exhibit 37: Sanofi: YoY revenue and growth rate of Lantus 2013-2015 ($ billions)
Exhibit 38: Sanofi: Lantus geographical segmentation by revenue 2015
Exhibit 39: Sanofi: YoY revenue and growth rate of Apidra 2013-2015 ($ millions)
Exhibit 40: Sanofi: YoY revenue and growth rate of Insuman 2013-2015 ($ millions)
Exhibit 41: Sanofi: Key takeaways
Exhibit 42: Eli Lilly: YoY revenue and growth rate of Humalog 2013-2015 ($ billions)
Exhibit 43: Eli Lilly: YoY revenue and growth rate of Humulin 2013-2015 ($ billions)
Exhibit 44: Eli Lilly: Key takeaways
...
Publisher Name : Technavio

SIMILAR MARKET STUDIES

Please Select Format
Single User: US $ 2500
Five User: US $ 3000
Site User: US $ 4000
Global User: US $ 10000

NEED MORE INFORMATION
Contact us
Call us +1-971-202-1575
--- or ---
help@bigmarketresearch.com
WHY BIG MARKET RESEARCH
With high quality and penned to perfection, Big Market Research is an exclusive online market to get best market research reports for your business needs and strategies. We recommend you to stop browsing as soon as you discover our website. This is because we firmly believe that once you reach here; all your business concerns will be addressed.

We have a huge collection of market research report from numerous filed which will provide you with all the necessary solution. We make sure that reports that we sell are true in context, have a quality that is unrivaled, fully integrated with equal spread of opinion. They will give you proper insights into different opportunities one may locate for their start-up pr expansion.

Let your qualms and concern be sidelined through our high end syndicated as well as customized reports.
Top